Badar, T., Szabo, A., Dinner, S., Liedtke, M., Burkart, M., Shallis, R. M., Yurkiewicz, I. R., Kuo, E., Khan, M. A., Balasubramanian, S., Yang, J., Hefazi, M., Podoltsev, N., Patel, A., Curran, E., Wang, A., Arslan, S., Aldoss, I., Siebenaller, C., Mattison, R. J., Litzow, M. R., Wadleigh, M., Advani, A. S., & Atallah, E. (2021). sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer, 127(7), 1039–1048. http://access.bl.uk/ark:/81055/vdc_100127439253.0x00005f